LibraryBy pinki shah / May 14, 2022 Speciality — Amyotrophic Lateral Sclerosis (ALS) Biomarkers Biosimilars Bladder Blood Bone Brain Breast Cancer Central Nervous System (CNS) Clinical Trials Colon Colorectal Diversity, Equity & Inclusion Featured Content Gastrointestinal Genitourinary Genomic Geriatric Gynecology Head and Neck Hematologic Hematologic Maglinencies Hematology Immunotherapy Interventional Radiology Kidney Leukemia Liquid Biopsy Liver Lung Lymphoma Malignencies Melanoma Myelodysplastic Syndrome Myeloma Neuroendocrine Novel Oral & Maxillofacial Surgery Ovarian Pancreas Pancreatic Pharmacological Prostate Radiation Radiology Renal Sarcoma Skin Solid Tumor Supportive & Palliative Care Survivorship Telemedicine Thoracic Thrombosis Thymic Thyroid Urothelial Author / Speaker Title of Presentation Type of Media — Video Document Audio Event 2024 Event — 2025 MaTOS Breast 2025 MaTOS GU 2025 PRIMO 2025 South Florida GI Cancer Symposium 2025 Winter Cancer Symposium (WCS) 2024 Advances in Oncology Conference 2024 Best of WCLC San Francisco 2024 California Cancer Consortium Conference (CCC) 2024 MaTOS Lungs 2024 MLS Cleveland 2024 MLS Irvine 2024 MLS Nashville 2024 MLS New Orleans 2024 MLS Seattle 2024 New Orleans Summer Cancer Meeting (NOSCM) 2024 PACC Miami 2024 PRIMO 2024 SPS Puerto Rico 2024 SPS Seattle 2024 SPECTRUM 2024 Sylvester APP Oncology Symposium 2024 Updates in Cancer Therapies 2024 WCS Clear Displaying 1,776 - 1,800 of 2,995 « 1 … 70 71 72 73 74 … 120 » RET, MET & B-RAF mutations in NSCLC By: Janakiraman Subramanian, MD, MPH View Video Managing Toxicities from TKI EGFR and ALK Inhibitors By: Jane Arboleda, APRN View PDF The Era of Antibody Drug Conjugates in NSCLC Targeting Her-2, CEACAM5, TROP-2, and MET By: Jason Porter, MD View PDF Small Cell Lung Cancer By: Jason Porter, MD View PDF The Era of Antibody Drug Conjugates in NSCLC Targeting Her-2, CEACAM5, TROP-2, and MET By: Jason Porter, MD View Video Small Cell Lung Cancer By: Jason Porter, MD View Video Target Therapy Updates in Lung Cancer 2024 By: JASON PORTER, MD View PDF Best Surgical Approaches for Stage III NSCLC By: Jay M. Lee, MD View PDF Best Surgical Approaches for Stage III NSCLC By: Jay M. Lee, MD View Video Perioperative Chemo/Immunotherapy and Surgical Outcomes By: Jay M. Lee, MD View PDF Brain Radiotherapy in SCLC: When? By: Jeffrey Bradley, MD View PDF Radiation Induced Immune-Response in NSCLC By: Jeffrey Bradley, MD View PDF Brain Radiotherapy in SCLC: When? By: Jeffrey Bradley, MD View Video Radiation Induced Immune-Response in NSCLC By: Jeffrey Bradley, MD View Video Mechanisms of Resistance to ALK Inhibitors By: Jessica Lin, MD View PDF Updates on Targeting ALK, ROS1 ,and RET in NSCLC By: Jessica Lin, MD View PDF Mechanisms of Resistance to ALK Inhibitors By: Jessica Lin, MD View Video Updates on Targeting ALK, ROS1 ,and RET in NSCLC By: Jessica Lin, MD View Video Immunotherapy in Lung Cancer By: Jhanelle E Gray, MD View Video Immunotherapy in Lung Cancer By: Jhanelle E. Gray, MD View PDF What’s After PACIFIC? Can We Raise the Bar? By: Jhanelle Gray, MD View PDF What’s After PACIFIC? Can We Raise the Bar? By: Jhanelle Gray, MD View Video ALK, ROS1, and BRAF Positive Lung Cancer By: Joel Neal, MD, PhD View PDF ALK, ROS1, and BRAF Positive Lung Cancer By: Joel Neal, MD, PhD View PDF ALK, ROS1, and BRAF Positive Lung Cancer By: Joel Neal, MD, PhD View Video
